How do multifood allergy treatments compare?

Investigators compared omalizumab with omalizumab-facilitated multiallergen oral immunotherapy.

Category	Detail
Condition	Multifood Allergy
Key Mechanisms	Omalizumab and multiallergen oral immunotherapy (MOIT)
Target Population	Patients aged 1 to 55 years with peanut allergy and allergies to at least 2 additional foods
Care Setting	Multicenter, double-blind, placebo-controlled clinical trial

36% of participants receiving omalizumab met the primary endpoint vs. 19% receiving MOIT
Serious adverse events occurred in 31% of those receiving MOIT vs. 0% receiving omalizumab
88% of participants receiving omalizumab completed the study vs. 51% receiving MOIT
72% of participants receiving omalizumab tolerated at least 444 mg of all 3 allergens vs. 39% receiving MOIT
Epinephrine was administered for adverse events in 37% of MOIT patients vs. 7% of omalizumab patients

Patients with multifood allergies and low baseline cumulative tolerated doses

Omalizumab may offer a higher rate of treatment success compared to MOIT

Consider individual patient needs and preferences when weighing treatment options
Monitor for eosinophilic esophagitis in patients receiving MOIT

Clinical Scorecard: How do multifood allergy treatments compare?